Take this to heart$ or just leave it BUT? You could lose out because the pps is set to climb abruptly!
Haleon and BioElectronics Corporation Collaboration
BioElectronics Corporation (BIEL) is not currently in a formal clinical trial with Haleon, but the two companies are in an active development and integration phase for Haleon’s Voltaren brand.
According to a March 2026 investor update, Haleon is developing “Voltaren ActiPatch hybrids” — wearable devices that combine traditional diclofenac topical gels with BIEL’s pulsed shortwave therapy (PSWT) technology to create a dual‑action “Super Patch” for chronic pain InvestorsHub. This is part of Haleon’s 2026–2027 innovation pipeline, which is repositioning ActiPatch as a mainstream recovery tool integrated into the Voltaren ecosystem.
Key points from the update:
Hybrid product development: Combines Haleon’s topical pain relief with BIEL’s wearable tech.
Swiss pilot (2027): A targeted rollout in Switzerland to serve as a proof‑of‑concept for broader European and global expansion InvestorsHub.
UEFA Champions League partnership: Haleon’s official licensing of Voltaren products for the 2025–2027 seasons will be used to drive trial and adoption among younger, tech‑savvy audiences Haleon.
Telemedicine integration: Haleon’s new “Digital Health & Telemedicine” distribution model will help ActiPatch move from niche medical device to a mainstream recovery tool InvestorsHub.
While the Swiss pilot and UEFA partnership are commercial and marketing initiatives, they are directly tied to BIEL’s ActiPatch technology and represent the current stage of collaboration — not a completed clinical trial. If the pilot is successful, it could lead to further clinical or market expansion.
Bottom line: BIEL and Haleon are in a product integration and market rollout phase, not a completed clinical trial. The next major milestone is the 2027 Swiss pilot, which could signal deeper clinical or commercial validation.
Haleon and BioElectronics Corporation Collaboration
BioElectronics Corporation (BIEL) is not currently in a formal clinical trial with Haleon, but the two companies are in an active development and integration phase for Haleon’s Voltaren brand.
According to a March 2026 investor update, Haleon is developing “Voltaren ActiPatch hybrids” — wearable devices that combine traditional diclofenac topical gels with BIEL’s pulsed shortwave therapy (PSWT) technology to create a dual‑action “Super Patch” for chronic pain InvestorsHub. This is part of Haleon’s 2026–2027 innovation pipeline, which is repositioning ActiPatch as a mainstream recovery tool integrated into the Voltaren ecosystem.
Key points from the update:
Hybrid product development: Combines Haleon’s topical pain relief with BIEL’s wearable tech.
Swiss pilot (2027): A targeted rollout in Switzerland to serve as a proof‑of‑concept for broader European and global expansion InvestorsHub.
UEFA Champions League partnership: Haleon’s official licensing of Voltaren products for the 2025–2027 seasons will be used to drive trial and adoption among younger, tech‑savvy audiences Haleon.
Telemedicine integration: Haleon’s new “Digital Health & Telemedicine” distribution model will help ActiPatch move from niche medical device to a mainstream recovery tool InvestorsHub.
While the Swiss pilot and UEFA partnership are commercial and marketing initiatives, they are directly tied to BIEL’s ActiPatch technology and represent the current stage of collaboration — not a completed clinical trial. If the pilot is successful, it could lead to further clinical or market expansion.
Bottom line: BIEL and Haleon are in a product integration and market rollout phase, not a completed clinical trial. The next major milestone is the 2027 Swiss pilot, which could signal deeper clinical or commercial validation.
2
